#Isomorphic Labs
7 articles with this tag
Demis Hassabis Steps Down as DeepMind CEO, Moves to AGI Focus
Demis Hassabis stepped down as CEO of Google DeepMind on August 5, 2026, taking on a chairman and Alphabet chief scientist role to focus on AGI strategy and Isomorphic Labs. The announcement came the same day Jeff Dean, Sanjay Ghemawat, Oriol Vinyals, and Quoc Le revealed they were leaving Google to co-found Discovery Loop. Alphabet shed roughly 5 percent of its market value on the news.
Demis Hassabis Turns DeepMind Into Alphabet's $205B AI Engine
Google Cloud jumped 82 pct to $24.8 billion in Q2 2026, with DeepMind's Gemini models at the center. Here's how Demis Hassabis underpins Alphabet's $205 billion AI capex commitment and Isomorphic Labs's $2.1 billion drug discovery bet.
DeepMind's Bioresilience Play
Google DeepMind and Isomorphic Labs are leveraging AI for bioresilience, focusing on prevention, detection, and response to global health threats.
Demis Hassabis Says Google Leads AI Talent Race as Researchers Defect
Hassabis told Semafor on June 23 that Google DeepMind still wins the AI talent war, days after four researchers joined Anthropic. Here is what his dual mandate at Isomorphic Labs and Alphabet's $20B Google Cloud quarter mean for that claim.
Demis Hassabis's Isomorphic Labs: $2.7B Raised, Trials Due This Year
Isomorphic Labs raised $2.7B total through May 2026. How the pharma deals with Lilly and Novartis work, what IsoDDE changed, and when trials begin.
Architectural Interactivity, Linguistic Interpretability, and Molecular Synthesis: The Frontier of Native AI
Three organisations now define the frontier of native AI: Thinking Machines is rebuilding human-AI collaboration as a low-latency interaction model, the Effable movement wants interpretable safety frameworks like SafetyAnalyst, and Isomorphic Labs is converting AlphaFold into an end-to-end drug design engine. The common thread is moving from AI as a layer of abstraction toward AI as a fundamental component of human and biological systems.
Demis Hassabis in 2026: How DeepMind Is Turning AlphaFold Into a Drug Discovery Engine
Demis Hassabis has spent 2026 arguing that AlphaFold is the first rung in an AI-powered scientific revolution. Here is how his thesis maps to Isomorphic Labs' drug pipeline, DeepMind's research agenda, and his view that the generative AI boom may paradoxically slow deeper progress.